SARS-CoV-2 Antibody

Home>Tag: SARS-CoV-2 Antibody
Jun 7 2021

Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies

By |2021-06-06T20:44:05-04:00June 7th, 2021|Featured, Investor News, News|0 Comments

Demonstrates Greater Binding Affinity Than Previous Antibodies Jackson Center, PA, June 7, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2, both with a stronger binding affinity than Halberd’s earlier announced monoclonal antibodies against Covid-19.  Each of these new antibodies bind to different ...

May 17 2021

Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody

By |2021-05-17T11:12:47-04:00May 17th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein.  This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...

Mar 30 2021

Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

By |2021-03-29T20:24:19-04:00March 30th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties.  This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...

Mar 9 2021

Halberd Corporation’s CEO Interviewed on “The Stock Day Podcast” – Focus on Halberd’s New 20x Affinity Neutralizing SARS-COV-2 Antibody

By |2021-03-08T20:35:16-05:00March 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly.  In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies ...

Mar 2 2021

Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

By |2021-03-01T20:05:18-05:00March 2nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...

Dec 23 2020

Halberd Corporation Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein

By |2020-12-22T21:04:30-05:00December 23rd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 23, 2020 – Halberd Corp. (OTC PINK: "HALB") research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein.  Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd’s initial antibody.  Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only ...

Dec 14 2020

Halberd Corp. Research Yields Potent SARS-CoV-2 Antibody

By |2020-12-13T17:40:49-05:00December 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication.  Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based ...

Go to Top